Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS

Jahr

2021

Autoren

Hersh CM, Kieseier B, de Moor C, Miller DM, Campagnolo D, Williams JR, Fitzgerald KC, Xiong K, McGinley MP, Hyland M, Rudick RA, Ziemssen T, Koulinska I.

Verlag

Mult Scler J Exp Transl Clin. 2021 Apr 15;7(2):20552173211004634.

Link

https://doi.org/10.1177/20552173211004634

Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS

Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis

From implementation to discontinuation: multi-year experience with the multiple sclerosis performance test as a digital monitoring tool

Machine learning integration of MRI and gait reveals mobility phenotypes in multiple sclerosis

Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing.

Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study